Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
06 Febbraio 2019 - 2:00PM
Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company
focused on transformational autologous cell-based therapies for
skin and connective tissue diseases, today announced that John
Maslowski, President and Chief Executive Officer, will present at
the 21st Annual BIO CEO & Investor Conference on Monday,
February 11 at 9:45 am EST in New York City. Mr. Maslowski will
discuss the Company’s gene therapy candidates for rare diseases:
FCX-007 for the treatment of recessive dystrophic epidermolysis
bullosa (RDEB), a devastating genetic skin disease with a high
mortality rate, and FCX-013 for the treatment of moderate to severe
localized scleroderma, a chronic, debilitating genetic skin
disorder with no therapies approved by the U.S. Food and Drug
Administration.
A live webcast of Fibrocell’s presentation will
be available under the Investors section of the Company’s website
at www.fibrocell.com/investors/events and a replay will be
available for 30 days following the event.
About
Fibrocell
Fibrocell is an autologous cell and gene therapy
company translating personalized biologics into medical
breakthroughs for diseases affecting the skin and connective
tissue. Fibrocell's most advanced product candidate, FCX-007,
is the subject of a Phase 1/2 clinical trial for the treatment of
RDEB. Fibrocell is also developing FCX-013, the Company's clinical
stage candidate for the treatment of moderate to severe localized
scleroderma. Fibrocell's gene therapy portfolio is being
developed in collaboration with Intrexon Corporation (NASDAQ: XON),
a leader in synthetic biology. For more information, visit
www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell®, the Fibrocell logo, and Fibrocell
Science® are trademarks of Fibrocell Science, Inc. and/or its
affiliates. All other names may be trademarks of their
respective owners.
Investor & Media Relations
Contact:Karen Casey484.713.6133kcasey@fibrocell.com
Grafico Azioni Fibrocell Science (NASDAQ:FCSC)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Fibrocell Science (NASDAQ:FCSC)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Fibrocell Science Inc (NASDAQ): 0 articoli recenti
Più Articoli Notizie